title: Alginate/poly (lactic-co-glycolic acid)/calcium phosphate cement scaffold with oriented pore structure for bone tissue engineering.
abstract: In this study, the alginate/calcium phosphate cement (CPC) scaffolds with oriented pore structure were fabricated by unidirectional freeze casting and poly (lactic-co-glycolic acid) (PLGA) was used to infiltrate into the macropores to strengthen the scaffolds. By modifying the liquid to powder ratio, the porosity and pore size of the alginate/CPC scaffold could be controlled. At the liquid to powder (L/P) ratio of 3.25, scaffolds possessing open directional macropores and a total porosity of 89.24% could be achieved. The size of the tubule-like macropores could reach 100-200 mum in their radial dimension and more than 1000 mum in the axial one, with macropores well-regulated arrayed. Increasing the L/P ratio would significantly decrease the mechanical strength of alginate/CPC scaffolds. The compressive strength and toughness of scaffolds could be greatly improved via PLGA reinforcement. Three mechanisms of PLGA reinforcement ran as follows: participating in the external load, strengthening the matrix, and patching the defects of CPC pores wall. Alginate/PLGA/CPC scaffold preserved the open directional macropores and might be a potential scaffold for bone tissue engineering.
authors.affiliation: Key Laboratory of Specially Functional Materials, Ministry of Education, South China University of Technology, Guangzhou 510641, China.
authors.forename: Xiaopeng
authors.initials: X
authors.lastname: Qi
authors.forename: Jiandong
authors.initials: J
authors.lastname: Ye
authors.forename: Yingjun
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000464:Alginates / Q000737:chemistry / Q000494:pharmacology*; D001696:Biomechanical Phenomena / Q000187:drug effects; D001843:Bone Cements / Q000494:pharmacology*; D001842:Bone and Bones / Q000187:drug effects*; D002130:Calcium Phosphates / Q000737:chemistry / Q000494:pharmacology*; D019245:Compressive Strength / Q000187:drug effects; D020723:Glucuronic Acid / Q000737:chemistry / Q000494:pharmacology; D006016:Glycolates / Q000494:pharmacology*; D006603:Hexuronic Acids / Q000737:chemistry / Q000494:pharmacology; D019344:Lactic Acid; D008422:Materials Testing; D008855:Microscopy, Electron, Scanning; D049329:Nanostructures; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D016062:Porosity / Q000187:drug effects; D023822:Tissue Engineering; D054457:Tissue Scaffolds; D014961:X-Ray Diffraction
chemical_list: D000464:Alginates; D001843:Bone Cements; D002130:Calcium Phosphates; D006016:Glycolates; D006603:Hexuronic Acids; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D020723:Glucuronic Acid; C020243:calcium phosphate